Next steps in the early detection of ovarian cancer

被引：0
作者：
Robert C. Bast
Chae Young Han
Zhen Lu
Karen H. Lu
机构：
[1] University of Texas M.D. Anderson Cancer Center,Department of Experimental Therapeutics
[2] University of Texas M.D. Anderson Cancer Center,Department of Gynecologic Oncology and Reproductive Medicine
来源：
Communications Medicine | / 1卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A recent ovarian cancer screening trial found no reduction in mortality, despite increased detection of early stage disease. Here, we discuss these findings and examine next steps to develop more effective approaches for the early detection of ovarian cancer.
引用
收藏
相关论文
共 16 条
[1]  
Menon U(2021)Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 397 2182-2193
[2]  
Jacobs IJ(2016)Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Lancet 387 945-956
[3]  
Fan D(2021)A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin Cancers 13 446-3461
[4]  
Lu KH(2013)A 2-stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value Cancer 119 3454-408
[5]  
Stott W(2018)Sonographers’ self‐reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images in UKCTOCS Ultrasound Obstet. Gynecol. 51 401-2512
[6]  
Bast RC(2020)Biomarkers and strategies for early detection of ovarian cancer Cancer Epidemiol. Biomark. Prev. 29 2504-400
[7]  
Simmons AR(2019)Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer Cancer Prev. Res. 12 391-736
[8]  
Yang WL(2019)Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer Cancer 126 725-5922
[9]  
Guo J(2019)Osteopontin, macrophage migration inhibitory factor and anti-interleukin-8 autoantibodies complement CA125 for detection of early stage ovarian cancer Cancers 11 596-930
[10]  
Yang WL(2017)Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer Clin. Cancer Res. 23 5912-1420
12